Application of physiologically based absorption and pharmacokinetic modeling in the development process of oral modified release generic products

被引:3
|
作者
Subhani, Saima [1 ]
Kim, Chaejin [1 ]
Muniz, Paula [2 ]
Rodriguez, Monica [2 ]
van Os, Sandra [3 ]
Suarez, Elena [4 ]
Cristofoletti, Rodrigo [1 ]
Schmidt, Stephan [1 ]
Vozmediano, Valvanera [1 ,5 ]
机构
[1] Univ Florida, Coll Pharm, Ctr Pharmacometr & Syst Pharmacol Lake Nona Orland, Dept Pharmaceut, Gainesville, FL USA
[2] CTI Co, Model Informed Dev MID, Dynakin, SLU, Bilbao, Spain
[3] Synthon BV, Nijmegen, Netherlands
[4] Univ Basque Country UPV EHU, Biocruces Hlth Res Inst, Fac Med & Nursery, Dept Pharmacol, Leioa, Spain
[5] Univ Florida, Coll Pharm, Ctr Pharmacometr & Syst Pharmacol CPSP, Dept Pharmaceut, 6550 Sanger Rd, Orlando, FL 32827 USA
关键词
Modified release drug products; Mechanistic modeling; Oral generic drug products; Modeling and simulation; In vitro-in vivo correlations (IVIVC); Physiologically based pharmacokinetic (PBPK); modeling for biopharmaceutics applications; Mechanistic absorption modeling; IN-VIVO CORRELATIONS; DOSAGE FORMS; FORMULATION DEVELOPMENT; PBPK ABSORPTION; VITRO; FOOD; PREDICTION; BIOAVAILABILITY; SOLUBILITY; COMPOUND;
D O I
10.1016/j.ejpb.2022.05.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Physiologically based pharmacokinetic (PBPK) modeling for biopharmaceutics applications holds great promise as modelling and simulation tool in the field of modern oral modified release (MR) products. Understanding of gastro-intestinal absorption related processes is crucial to ensure the successful development of complex oral drug generic products. In the recent years, PBPK approach has been gradually influencing decision making ability of pharmaceutical industry as well as regulatory agencies. However, there is a gap in understanding its contribution in the field of oral modified release products. In this review, we have collected different recent research articles illustrating the significant contribution of PBPK to the research and development process of oral MR products, with special emphasis on generic drug products. Concretely, literature examples on the utility of PBPK formulation development, for in vitro- in vivo correlations (IVIVC) and prediction of oral bioavailability, and for in-silico food effect predictions were included in the review.
引用
收藏
页码:87 / 94
页数:8
相关论文
共 50 条
  • [41] Application of Physiologically Based Pharmacokinetic Modeling to Understanding the Clinical Pharmacokinetics of UK-369,003
    Watson, Kenny J.
    Davis, John
    Jones, Hannah M.
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (07) : 1203 - 1213
  • [42] Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption
    Willmann, Stefan
    Edginton, Andrea N.
    Kleine-Besten, Marcus
    Jantratid, Ekarat
    Thelen, Kirstin
    Dressman, Jennifer B.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2009, 61 (07) : 891 - 899
  • [43] Application of physiologically based pharmacokinetic modeling of novel drugs approved by the US food and drug administration
    Sun, Zexu
    Zhao, Nan
    Zhao, Xia
    Wang, Ziyang
    Liu, Zhaoqian
    Cui, Yimin
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 200
  • [44] Physiologically Based Pharmacokinetic Modeling of Deltamethrin: Development of a Rat and Human Diffusion-Limited Model
    Godin, Stephen J.
    DeVito, Michael J.
    Hughes, Michael F.
    Ross, David G.
    Scollon, Edward J.
    Starr, James M.
    Setzer, R. Woodrow
    Conolly, Rory B.
    Tornero-Velez, Rogelio
    TOXICOLOGICAL SCIENCES, 2010, 115 (02) : 330 - 343
  • [45] Systemic Concentrations Can Limit the Oral Absorption of Poorly Soluble Drugs: An Investigation of Non-Sink Permeation Using Physiologically Based Pharmacokinetic Modeling
    Chiang, Po-Chang
    La, Hank
    Zhang, Haiming
    Wong, Harvey
    MOLECULAR PHARMACEUTICS, 2013, 10 (11) : 3980 - 3988
  • [46] Bottom-Up Physiologically Based Oral Absorption Modeling of Free Weak Base Drugs
    Matsumura, Naoya
    Ono, Asami
    Akiyama, Yoshiyuki
    Fujita, Takuya
    Sugano, Kiyohiko
    PHARMACEUTICS, 2020, 12 (09) : 1 - 18
  • [47] Application of physiologically based pharmacokinetic models to promote the development of veterinary drugs with high efficacy and safety
    Zhou, Kaixiang
    Mi, Kun
    Ma, Wenjin
    Xu, Xiangyue
    Huo, Meixia
    Algharib, Samah Attia
    Pan, Yuanhu
    Xie, Shuyu
    Huang, Lingli
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2021, 44 (05) : 663 - 678
  • [48] Physiologically-Based Pharmacokinetic Modeling to Support Determination of Bioequivalence for Dermatological Drug Products: Scientific and Regulatory Considerations
    Tsakalozou, Eleftheria
    Alam, Khondoker
    Babiskin, Andrew
    Zhao, Liang
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (05) : 1036 - 1049
  • [49] Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure
    Mukherjee, Dwaipayan
    Chiney, Manoj S.
    Shao, Xi
    Ju, Tzuchi R.
    Shebley, Mohamad
    Marroum, Patrick
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2022, 43 (03) : 98 - 107
  • [50] Using Physiologically Based Pharmacokinetic Modeling to Assess the Risks of Failing Bioequivalence Criteria: a Tale of Two Ibuprofen Products
    Loisios-Konstantinidis, Ioannis
    Hens, Bart
    Mitra, Amitava
    Kim, Sarah
    Chiann, Chang
    Cristofoletti, Rodrigo
    AAPS JOURNAL, 2020, 22 (05)